patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation
Conditions
Interventions
Trade Name: Revlimid
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Lenalidomid
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Trade Name: Revlimid
Ph
Sponsors
Technische Universität Dresden
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Understand and voluntarily sign an informed consent form. 2. Age >=18 years at the time of signing the informed consent form. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. - AML (>=20% blasts) including secondary (s)AML (after radio-chemotherapy) with karyotype abnormalities involving monosomy 5 or del5q or - MDS and sMDS RAEB-1 and RAEB-2 with karyotype abnormalities involving monosomy 5 or del5q or - MDS and sMDS type RA(+/-RS) or RCMD(+/-RS) only with complex karyotype abnormalities involving monosomy 5 or del5q 5. in complete hematological remission documented by bone marrow aspiration within 8-16 weeks after allogeneic HSCT 6. All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study. 7. ECOG performance status of =1.0 x 109/L - Platelet count >=100 x 109/L - Serum creatinine =5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma “in situ” of the cervix or breast 11. Able to take aspirin (ASA) 100mg daily as prophylactic anticoagulation in case of concomitant steroid treatment (patients intolerant to ASA may use low molecular weight heparin). Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. 2. active acute GVHD grade 2-4 3. Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide). 4. History of arterial or venous embolism or stroke 5. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. 6. Use of any other experimental drug or therapy to treat MDS or AML within 28 days of baseline. 7. Known hypersensitivity to thalidomide or lenalidomide. 8. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. 9. Any prior use of lenalidomide 10. Concurrent use of other investigational treatments 11. Known positive for HIV or infectious hepatitis, type A, B or C.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): Cumulative incidence of relapse rate at 1 year post transplantation;Main Objective: To determine whether lenalidomide maintenance therapy in MDS or AML patients with monosomy 5 or del5q abnormalities after allogeneic HSCT can result in a relapse rate = 50%;Secondary Objective: Determine the safety of lenalidomide when given after allogeneic HSCT | — |
Countries
Germany
Outcome results
None listed